Spleen tyrosine kinase (Syk) is a protein tyrosine kinase involved in a variety of biological activities. Spleen tyrosine kinase (Syk) is a non-receptor cytosolic protein tyrosine kinase (PTK) that is mostly found in hematopoietic cells. Syk has been identified as an important B-cell receptor signaling cascade component. Other immunological receptors, such as Fc receptors and adhesion receptors, rely on Syk for signal transmission.
This report contains market size and forecasts of Spleen Tyrosine Kinase (Syk) Inhibitor Therapeutics in Global, including the following market information:
Global Spleen Tyrosine Kinase (Syk) Inhibitor Therapeutics Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Spleen Tyrosine Kinase (Syk) Inhibitor Therapeutics market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period 2022-2028.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
DNA Sequencing Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Spleen Tyrosine Kinase (Syk) Inhibitor Therapeutics include F. Hoffmann-La Roche, Mylan N.V., Teva Pharmaceutical Industries, Bayer, AstraZeneca, Rigel Pharmaceuticals, Gilead Sciences, Novartis and Pfizer, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Spleen Tyrosine Kinase (Syk) Inhibitor Therapeutics companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Spleen Tyrosine Kinase (Syk) Inhibitor Therapeutics Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Spleen Tyrosine Kinase (Syk) Inhibitor Therapeutics Market Segment Percentages, by Type, 2021 (%)
DNA Sequencing
Polymerase Chain Reaction
Mass Spectrometry
Microarray
Electrophoresis
Global Spleen Tyrosine Kinase (Syk) Inhibitor Therapeutics Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Spleen Tyrosine Kinase (Syk) Inhibitor Therapeutics Market Segment Percentages, by Application, 2021 (%)
Clinic
Hospital
Others
Global Spleen Tyrosine Kinase (Syk) Inhibitor Therapeutics Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Spleen Tyrosine Kinase (Syk) Inhibitor Therapeutics Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Spleen Tyrosine Kinase (Syk) Inhibitor Therapeutics revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Spleen Tyrosine Kinase (Syk) Inhibitor Therapeutics revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
F. Hoffmann-La Roche
Mylan N.V.
Teva Pharmaceutical Industries
Bayer
AstraZeneca
Rigel Pharmaceuticals
Gilead Sciences
Novartis
Pfizer
Bristol-Myers Squibb Company
Johnson & Johnson Private Limited
Thermo Fisher Scientific
OPKO Health
Myriad Genetics
QIAGEN
OneOme